Tri-nymyo Kit
Product Images NDC 51862-646

Product Visual Gallery

This gallery contains 11 technical images submitted to the FDA as part of the official labeling for Tri-nymyo (NDC 51862-646). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Mayne Pharma Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

1 (Image 01)

Table of administration instructions for Tri-Nymyo kit, detailing starting schedules for women not currently using hormonal contraception, Sunday start guidance, and guidelines for switching from other contraceptive methods including transdermal patch, vaginal ring, injection, intrauterine contraceptive, and implant. It covers tablet colors, timing, and additional contraception recommendations during initial use.*

FDA Label Image

2 (Image 02)

Table presenting instructions for missed Tri-Nymyo tablets, detailing actions to take if one or two active tablets are missed in Weeks 1, 2, or 3, and guidance for multiple missed tablets in the third week or consecutively across weeks. It includes advice on restarting the pack and use of additional non-hormonal contraception as back-up.*

FDA Label Image

3 (Image 03)

Chemical structure diagram showing the molecular formulas of Norgestimate and Ethinyl Estradiol, the active ingredients in Tri-Nymyo.*

FDA Label Image

4 (Image 04)

A data table titled 'Summary of norelgestromin, norgestrel and ethinyl estradiol pharmacokinetic parameters' presenting mean and standard deviation values for pharmacokinetic parameters (Cmax, tmax, AUC0-24h, and t½) of these analytes during a three-cycle study of norgestimate/ethinyl estradiol tri-cyclic tablets at various dosages. The table includes values by cycle and day, with abbreviations and units defined below the table.*

FDA Label Image

5 (Image 05)

A data table presenting acne vulgaris indications comparing norgestimate and ethinyl estradiol tri-cycle tablets versus placebo in two multicenter, placebo-controlled trials. The table shows baseline and six-month mean counts and percentage reductions of inflammatory, non-inflammatory, and total lesions, along with differences and confidence intervals at six months.*

FDA Label Image

6 (Image 06)

FDA Label Image

7 (Image 07)

Illustration showing a vertical scale correlating pregnancy rates per 100 women in one year with contraceptive methods. Fewer pregnancies are associated with implants, injections, intrauterine devices, sterilization, birth control pills, skin patches, and vaginal rings with hormones. Moderate pregnancy rates correspond to condoms and diaphragms, while higher rates relate to methods like no sex during fertile days, spermicide, withdrawal, and the highest rates indicate no birth control use.*

FDA Label Image

8 (Image 08)

Tri-Nymyo 28 Tablet Blister Card kit with tablets arranged in weekly rows labeled by day and color-coded by week: green for week 1, light blue for week 2, blue for week 3, and white for week 4. The label indicates the active ingredients as norgestimate and ethinyl estradiol tablets, with specific dosing instructions to take pills left to right each week. The labeler is Mayne Pharma Inc.*

FDA Label Image

9 (Image 09)

An instructional diagram illustrating how to use the Tri-Nymyo kit, showing a hand placing a day label sticker on the pill pack to correspond with the first day of the user's period. The pack contains four rows of pills in green, light blue, blue, and white colors labeled as Week 1 to Week 4. Arrows indicate the direction to take the pills left to right each week, with text instructions for Sunday starters and day 1 starters.*

FDA Label Image

10 (Image 10)

FDA Label Image

11 (Image 11)

Packaging label for Tri-Nymyo, a kit of Norgestimate and Ethinyl Estradiol tablets USP with strengths 0.18 mg, 0.035 mg, 0.215 mg, and 0.25 mg per tablet. The carton indicates a 28-day regimen with 6 blister cards of 28 tablets each. Labeler is Mayne Pharma Inc., with NDC 51862-646-06. The label includes usage instructions, storage conditions, and cautionary statements.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.